<div>1.
Grassberger C, Shinnick D, Yeap BY, et al. Circulating Lymphocyte Counts
Early During Radiation Therapy Are Associated With Recurrence in
Pediatric Medulloblastoma. <i>Int J Radiat Oncol Biol Phys</i> . Jul 15
2021;110(4):1044-1052. doi:10.1016/j.ijrobp.2021.01.035</div><div>2. Upadhyay R, Venkatesulu BP, Giridhar P, et al. Risk and impact of
radiation related lymphopenia in lung cancer: A systematic review and
meta-analysis. <i>Radiother Oncol</i> . Apr 2021;157:225-233.
doi:10.1016/j.radonc.2021.01.034</div><div>3. Venkatesulu B, Giridhar P, Pujari L, et al. Lymphocyte sparing normal
tissue effects in the clinic (LymphoTEC): A systematic review of dose
constraint considerations to mitigate radiation-related lymphopenia in
the era of immunotherapy. <i>Radiother Oncol</i> . Dec 2022;177:81-94.
doi:10.1016/j.radonc.2022.10.019</div><div>4. Damen PJJ, Kroese TE, van Hillegersberg R, et al. The Influence of
Severe Radiation-Induced Lymphopenia on Overall Survival in Solid
Tumors: A Systematic Review and Meta-Analysis. <i>Int J Radiat Oncol
Biol Phys</i> . Nov 15 2021;111(4):936-948.
doi:10.1016/j.ijrobp.2021.07.1695</div><div>5. Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of
the influence of radiation-induced lymphopenia on survival outcomes in
solid tumors. <i>Crit Rev Oncol Hematol</i> . Mar 2018;123:42-51.
doi:10.1016/j.critrevonc.2018.01.003</div><div>6. Mallick S, V RA, Giridhar P, et al. A Systematic Review and
Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes
in High-Grade Gliomas. <i>South Asian J Cancer</i> . Oct
2022;11(4):361-369. doi:10.1055/s-0042-1753504</div><div>7. Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and
immunotherapy in brain tumours. <i>Nat Rev Cancer</i> . Jan
2020;20(1):12-25. doi:10.1038/s41568-019-0224-7</div><div>8. Audi ZF, Saker Z, Rizk M, et al. Immunosuppression in
Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.<i>Curr Treat Options Oncol</i> . Jul 30 2021;22(9):83.
doi:10.1007/s11864-021-00874-9</div><div>9. Bockmayr M, Mohme M, Klauschen F, et al. Subgroup-specific immune and
stromal microenvironment in medulloblastoma. <i>Oncoimmunology</i> .
2018;7(9):e1462430. doi:10.1080/2162402X.2018.1462430</div><div>10. Patel S, Wang S, Snuderl M, Karajannis MA. Pre-treatment lymphopenia
and indication of tumor-induced systemic immunosuppression in
medulloblastoma. <i>J Neurooncol</i> . Feb 2018;136(3):541-544.
doi:10.1007/s11060-017-2678-3</div><div>11. Gajjar A, Robinson GW, Smith KS, et al. Outcomes by Clinical and
Molecular Features in Children With Medulloblastoma Treated With
Risk-Adapted Therapy: Results of an International Phase III Trial
(SJMB03). <i>J Clin Oncol</i> . Mar 1 2021;39(7):822-835.
doi:10.1200/JCO.20.01372</div><div>12. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted
craniospinal radiotherapy followed by high-dose chemotherapy and
stem-cell rescue in children with newly diagnosed medulloblastoma (St
Jude Medulloblastoma-96): long-term results from a prospective,
multicentre trial. <i>Lancet Oncol</i> . Oct 2006;7(10):813-20.
doi:10.1016/S1470-2045(06)70867-1</div><div>13. Wang F, Cathcart SJ, DiMaio DJ, et al. Comparison of tumor immune
environment between newly diagnosed and recurrent glioblastoma including
matched patients. <i>J Neurooncol</i> . Aug 2022;159(1):163-175.
doi:10.1007/s11060-022-04053-0</div><div>14. Turner CP, McLay J, Hermans IF, et al. Tumour infiltrating
lymphocyte density differs by meningioma type and is associated with
prognosis in atypical meningioma. <i>Pathology</i> . Jun
2022;54(4):417-424. doi:10.1016/j.pathol.2021.10.002</div><div>15. Pages F, Mlecnik B, Marliot F, et al. International validation of
the consensus Immunoscore for the classification of colon cancer: a
prognostic and accuracy study. <i>Lancet</i> . May 26
2018;391(10135):2128-2139. doi:10.1016/S0140-6736(18)30789-X</div><div>16. Bienkowski M, Preusser M. Prognostic role of tumour-infiltrating
inflammatory cells in brain tumours: literature review. <i>Curr Opin
Neurol</i> . Dec 2015;28(6):647-58. doi:10.1097/WCO.0000000000000251</div><div>17. Shadbad MA, Asadzadeh Z, Hosseinkhani N, et al. A Systematic Review
of the Tumor-Infiltrating CD8(+) T-Cells/PD-L1 Axis in High-Grade Glial
Tumors: Toward Personalized Immuno-Oncology. <i>Front Immunol</i> .
2021;12:734956. doi:10.3389/fimmu.2021.734956</div><div>18. Kmiecik J, Poli A, Brons NH, et al. Elevated CD3+ and CD8+
tumor-infiltrating immune cells correlate with prolonged survival in
glioblastoma patients despite integrated immunosuppressive mechanisms in
the tumor microenvironment and at the systemic level. <i>J
Neuroimmunol</i> . Nov 15 2013;264(1-2):71-83.
doi:10.1016/j.jneuroim.2013.08.013</div><div>19. Mauldin IS, Jo J, Wages NA, et al. Proliferating CD8(+) T Cell
Infiltrates Are Associated with Improved Survival in Glioblastoma.<i>Cells</i> . Dec 1 2021;10(12)doi:10.3390/cells10123378</div><div>20. Safaei S, Mohme M, Niesen J, Schuller U, Bockmayr M. DIMEimmune:
Robust estimation of infiltrating lymphocytes in CNS tumors from DNA
methylation profiles. <i>Oncoimmunology</i> . 2021;10(1):1932365.
doi:10.1080/2162402X.2021.1932365</div><div>21. Sharma R, Katiyar V, Gurjar H, Sharma M, Goda R, Vora Z. Is
medulloblastoma associated with systemic immunomodulation? - A
comparative analysis of preoperative inflammatory markers. <i>Surg
Neurol Int</i> . 2020;11:86. doi:10.25259/SNI_336_2019</div><div>22. Grabovska Y, Mackay A, O’Hare P, et al. Pediatric pan-central
nervous system tumor analysis of immune-cell infiltration identifies
correlates of antitumor immunity. <i>Nat Commun</i> . Aug 28
2020;11(1):4324. doi:10.1038/s41467-020-18070-y</div><div>23. Vermeulen JF, Van Hecke W, Adriaansen EJM, et al. Prognostic
relevance of tumor-infiltrating lymphocytes and immune checkpoints in
pediatric medulloblastoma. <i>Oncoimmunology</i> . 2018;7(3):e1398877.
doi:10.1080/2162402X.2017.1398877</div><div>24. Murata D, Mineharu Y, Arakawa Y, et al. High programmed cell death 1
ligand-1 expression: association with CD8+ T-cell infiltration and poor
prognosis in human medulloblastoma. <i>J Neurosurg</i> . Mar
2018;128(3):710-716. doi:10.3171/2016.11.JNS16991</div><div>25. Ebrahimi S, Lim G, Liu A, et al. Radiation-Induced Lymphopenia Risks
of Photon Versus Proton Therapy for Esophageal Cancer Patients.<i>Int J Part Ther</i> . Fall 2021;8(2):17-27. doi:10.14338/IJPT-20-00086</div><div>26. Gaikwad U, Bajpai J, Jalali R. Combinatorial approach of
immuno-proton therapy in cancer: Rationale and potential impact.<i>Asia Pac J Clin Oncol</i> . May 16 2023;doi:10.1111/ajco.13966</div><div>27. De B, Ng SP, Liu AY, et al. Radiation-Associated Lymphopenia and
Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated
with Radiotherapy. <i>J Hepatocell Carcinoma</i> . 2021;8:57-69.
doi:10.2147/JHC.S282062</div><div>28. Cunningham D, Zaniletti I, Breen W, et al. Lymphopenia in Pediatric
Patients Following Proton Radiotherapy. <i>Int J Radiat Oncol Biol
Phys</i> . Nov 1 2021;111(3)(Supplement):e173.</div><div>29. Chou B, Hopper A, Elster J, et al. Volumetric de-escalation and
improved acute toxicity with proton craniospinal irradiation using a
vertebral body-sparing technique. <i>Pediatr Blood Cancer</i> . May
2022;69(5):e29489. doi:10.1002/pbc.29489</div><div>30. Ellis RE. The distribution of active bone marrow in the adult.<i>Phys Med Biol</i> . Jan 1961;5:255-8. doi:10.1088/0031-9155/5/3/302</div><div>31. Liu KX, Ioakeim-Ioannidou M, Susko MS, et al. A Multi-institutional
Comparative Analysis of Proton and Photon Therapy-Induced Hematologic
Toxicity in Patients With Medulloblastoma. <i>Int J Radiat Oncol Biol
Phys</i> . Mar 1 2021;109(3):726-735. doi:10.1016/j.ijrobp.2020.09.049</div>